Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Large B-Cell, Diffuse 2Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Cyclophosphamide 27Rituximab 26fludarabine phosphate 18Filgrastim 17fludarabine 13Lenalidomide 13Peripheral Blood Stem Cell Transplantation 12Bortezomib 12Bendamustine Hydrochloride 12ibrutinib 9venetoclax 8Etoposide 8Paclitaxel 7Flow Cytometry 7Cyclosporine 7tanespimycin 6aldesleukin 6Prednisone 6Magnetic Resonance Spectroscopy 6Cytarabine 6Biopsy 6obinutuzumab 5Vorinostat 5Tacrolimus 5Radiotherapy 5Polymerase Chain Reaction 5Melphalan 5Gemcitabine 5sargramostim 4belinostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell, Marginal Zone × obatoclax × Clear all
NCT00538187 2015-12-04

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡